NCT00700193View on ClinicalTrials.gov

A Study of the Safety, Tolerability & Immunogenicity of CSL Limited's Influenza Virus Vaccine In a Paediatric Population

PHASE3CompletedINTERVENTIONAL
Enrollment

298

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

June 30, 2006

Conditions
Influenza
Interventions
BIOLOGICAL

Influenza Virus Vaccine

2 dose vaccine regimen: 2 X 0.25mL vaccinations 30 days apart and a booster vaccination was administered 12 months after the first dose

BIOLOGICAL

Influenza Virus Vaccine

2 dose vaccine regimen: 2 X 0.50mL vaccinations 30 days apart and a booster vaccination was administered 12 months after the first dose

Trial Locations (1)

3052

Murdoch Childrens Research Institute, Melbourne

All Listed Sponsors
lead

Seqirus

INDUSTRY

NCT00700193 - A Study of the Safety, Tolerability & Immunogenicity of CSL Limited's Influenza Virus Vaccine In a Paediatric Population | Biotech Hunter | Biotech Hunter